Shanghai Vitalgen Biopharma Co., Ltd.

This study tests a new treatment called VGR-R01 for people with Bietti Crystalline Dystrophy, a rare inherited eye disease that leads to vision loss. The trial involves 45 adults who will receive the treatment or be in a control group. The main goal is to see if the treatment imp…

This study tests a new gene therapy called VGN-R09b in 39 people with Parkinson's disease. The goal is to see if it is safe and can help control motor symptoms like tremors and stiffness. Participants must have at least 2.5 hours of 'off' time per day despite standard treatment. …

This early-stage study tests a new gene therapy called VGR-R01 in 12 adults with Bietti Crystalline Dystrophy, a rare inherited eye disease that causes vision loss. The main goal is to check if the treatment is safe and tolerable. Researchers will monitor for side effects and cha…

This trial tests a gene therapy called VGN-R09b for children aged 1.5 to 8 years with severe AADC deficiency, a rare genetic disorder that severely limits movement. The treatment is injected directly into a brain region called the putamen. The study aims to see if it is safe and …